Study to Assess Safety of AZD7762 Administered Alone and in Combination with Gemcitabine in Patients with Advanced Solid Malignancies
Study identifier:D1040C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination with Weekly Standard Dose Gemcitabine in Patients with Advanced Solid Malignancies
Medical condition
Solid Tumors
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD7762, Gemcitabine
Sex
All
Actual Enrollment
42
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Dec 2006
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD7762 monotherapy followed by AZD7762 + gemcitabine | Drug: AZD7762 intravenous infusion Drug: Gemcitabine weekly intravenous infusion Other Name: Gemzar® Other Name: Gemcitabine HCL |
Contacts
Investigators
Principal Investigator
Peter Langmuir
AstraZeneca
